PuraPharm Corporation Limited

SEHK:1498 Stock Report

Market Cap: HK$160.5m

PuraPharm Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Abraham Chan

Chief executive officer

HK$3.7m

Total compensation

CEO salary percentage60.88%
CEO tenure14.4yrs
CEO ownership24.7%
Management average tenureno data
Board average tenure10.2yrs

Recent management updates

Analysis Article • May 20

Increases to PuraPharm Corporation Limited's (HKG:1498) CEO Compensation Might Cool off for now

Key Insights PuraPharm will host its Annual General Meeting on 27th of May Salary of HK$3.70m is part of CEO Abraham...

Recent updates

Analysis Article • May 20

Increases to PuraPharm Corporation Limited's (HKG:1498) CEO Compensation Might Cool off for now

Key Insights PuraPharm will host its Annual General Meeting on 27th of May Salary of HK$3.70m is part of CEO Abraham...
Analysis Article • Feb 21

PuraPharm Corporation Limited's (HKG:1498) Shares Lagging The Industry But So Is The Business

When you see that almost half of the companies in the Pharmaceuticals industry in Hong Kong have price-to-sales ratios...
Analysis Article • Feb 06

Risks To Shareholder Returns Are Elevated At These Prices For PuraPharm Corporation Limited (HKG:1498)

There wouldn't be many who think PuraPharm Corporation Limited's ( HKG:1498 ) price-to-sales (or "P/S") ratio of 0.7x...
Analysis Article • Sep 28

Is PuraPharm (HKG:1498) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Nov 02

PuraPharm (HKG:1498) Has Debt But No Earnings; Should You Worry?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Aug 23

Is PuraPharm (HKG:1498) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Apr 01

PuraPharm's (HKG:1498) Profits Appear To Have Quality Issues

PuraPharm Corporation Limited's ( HKG:1498 ) robust recent earnings didn't do much to move the stock. However the...
Analysis Article • Dec 27

How Much Is PuraPharm Corporation Limited (HKG:1498) Paying Its CEO?

The CEO of PuraPharm Corporation Limited ( HKG:1498 ) is Abraham Chan, and this article examines the executive's...

CEO Compensation Analysis

How has Abraham Chan's remuneration changed compared to PuraPharm's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025HK$4mHK$2m

-HK$35m

Sep 30 2025n/an/a

-HK$37m

Jun 30 2025n/an/a

-HK$39m

Mar 31 2025n/an/a

-HK$37m

Dec 31 2024HK$4mHK$4m

-HK$35m

Sep 30 2024n/an/a

-HK$61m

Jun 30 2024n/an/a

-HK$87m

Mar 31 2024n/an/a

-HK$97m

Dec 31 2023HK$6mHK$4m

-HK$106m

Sep 30 2023n/an/a

-HK$112m

Jun 30 2023n/an/a

-HK$118m

Mar 31 2023n/an/a

-HK$119m

Dec 31 2022HK$4mHK$4m

-HK$120m

Sep 30 2022n/an/a

-HK$147m

Jun 30 2022n/an/a

-HK$174m

Mar 31 2022n/an/a

-HK$148m

Dec 31 2021HK$4mHK$4m

-HK$122m

Sep 30 2021n/an/a

-HK$45m

Jun 30 2021n/an/a

HK$32m

Mar 31 2021n/an/a

HK$32m

Dec 31 2020HK$4mHK$3m

HK$32m

Sep 30 2020n/an/a

-HK$69m

Jun 30 2020n/an/a

-HK$171m

Mar 31 2020n/an/a

-HK$199m

Dec 31 2019HK$3mHK$1m

-HK$227m

Compensation vs Market: Abraham's total compensation ($USD474.83K) is above average for companies of similar size in the Hong Kong market ($USD238.72K).

Compensation vs Earnings: Abraham's compensation has been consistent with company performance over the past year.

CEO

Abraham Chan (64 yo)

14.4yrs
Tenure
HK$3,719,000
Compensation

Mr. Yu Ling Chan, also known as Abraham, BASc C.Eng. MIStruct E. P.Eng., has been the Chief Executive Officer and Chairman of PuraPharm Corporation Limited. Mr. Chan has been a Director at PuraPharm Corpor...

Board Members

NamePositionTenureCompensationOwnership
Yu Ling Chan
Founder14.4yrsHK$3.72m24.69%
HK$ 39.6m
Kam Biu Tsoi
Executive Directorless than a yearHK$724.00kno data
Yee Wai Man
Executive Director14.4yrsHK$1.29m0.036%
HK$ 57.1k
Bruce G. Robinson
Chairman of Scientific Advisory Committee10.2yrsno datano data
Lap-Chee Tsui
Independent Non-Executive Director10.9yrsHK$200.00k0.0034%
HK$ 5.4k
Lim Kin Leung
Independent Non-Executive Director10.9yrsHK$200.00k0.0034%
HK$ 5.4k
Piu Chan
Member of Scientific Advisory Committeeno datano datano data
Rudolf Bauer
Member of Scientific Advisory Committeeno datano datano data
Song Ming Liang
Member of Scientific Advisory Committeeno datano datano data
Chi Ming Che
Member of Scientific Advisory Committee4.3yrsno datano data
Kwok Keung Leung
Non-Executive Director2.9yrsHK$200.00kno data
Ting On Hung
Independent Non-Executive Directorless than a yearHK$68.00kno data
10.2yrs
Average Tenure
68yo
Average Age

Experienced Board: 1498's board of directors are seasoned and experienced ( 10.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/19 19:14
End of Day Share Price 2026/05/19 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PuraPharm Corporation Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ajeya PatilEvaluate Research Limited